Elicio Therapeutics (9HA) Financial Statements
Elicio Therapeutics Financial Overview
Elicio Therapeutics's market cap is currently $40.75M. The company's EPS TTM is $-2.13; its P/E ratio is -0.79; Elicio Therapeutics has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 28.31M |
| Gross Profit | $ -1.13M | $ -1.18M | $ -1.17M | $ -1.06M | $ 27.08M |
| Operating Income | $ -37.71M | $ -44.99M | $ -35.74M | $ -23.73M | $ -39.31M |
| EBITDA | $ -37.31M | $ -50.27M | $ -32.97M | $ -23.55M | $ -52.47M |
| Net Income | $ -39.57M | $ -51.90M | $ -35.20M | $ -28.21M | $ -26.40M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 18.56M | $ 17.62M | $ 12.89M | $ 7.80M | $ 88.76M |
| Total Assets | $ 25.86M | $ 28.18M | $ 27.15M | $ 22.66M | $ 96.51M |
| Total Debt | $ 14.51M | $ 26.04M | $ 6.92M | $ 7.48M | $ 4.66M |
| Net Debt | $ -4.05M | $ 8.42M | $ -5.98M | $ -316.00K | $ -84.09M |
| Total Liabilities | $ 24.23M | $ 39.49M | $ 15.77M | $ 13.75M | $ 15.01M |
| Stockholders' Equity | $ 1.64M | $ -11.31M | $ 11.37M | $ 8.91M | $ 81.51M |
| Cash Flow | |||||
| Free Cash Flow | $ -36.97M | $ -37.16M | $ -32.76M | $ -22.83M | $ -24.46M |
| Operating Cash Flow | $ -36.95M | $ -37.07M | $ -32.69M | $ -22.18M | $ -23.94M |
| Investing Cash Flow | $ -16.00K | $ -84.00K | $ -32.00K | $ -654.00K | $ -525.36K |
| Financing Cash Flow | $ 36.70M | $ 42.32M | $ 38.61M | $ 21.20M | $ 19.39M |
Currency in USD
